So help me out here. What's the appealing attribute?
Less insulin release? Therefore one can curtail insulinogenic-related response and the correlating sides (lethargy, etc)? Still though; where is the evidence these products have any distinct lipolytic advantage when someone ingests carbs?
Insulin is obviously lipogenic and anti-lipolytic so is this perhaps the appeal as well? To quell insulin response thus not allowing insulin to thwart lipolysis?
I think most approach it thinking the body has a hierarchy for storage. So up to a point, all nutrients are going to go to other places first (brain, organs, muscles, etc) with adipose tissue being the last place. So if you are in a slight caloric surplus then the extra nutrients are going to be shuttled to your muscles but if you are in a huge surplus, like taking a GDA and them binge eating, then after everything else gets their fill those nutrients are going to be shuttled to adipose.
Some GDAs, such as recompadrol, add compounds in to try and prevent adipose differentiation so to limit this. RecompMan will prolly be able to shed some light on this far better than I. I am kinda just thinking out loud here.
TUDCA is one of the only ones I know of but you need an extremely high dose (1750mg I believe was used in the study) and that would be very very expensive.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.